Back to Search Start Over

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Source :
PR Newswire. January 13, 2025
Publication Year :
2025

Abstract

-- Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naȯve Myelofibrosis Anticipated [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.823298118